Effects of cicletanine on the progression of renal failure in 5/6 nephrectomized hypertensive rats

Clinical and Experimental Pharmacology and Physiology

Volumn 26, Issue 3, 1999, Pages 236-241

  Nakamoto, Hidetomo ^a   Suzuki, Hiromichi ^a   Ohishi, Akira ^b   Katsumata, Hiroshige ^b   Sakaguchi, Hiroshi ^b   Saruta, Takao ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Cicletanine; Hypertension; Renal failure

Indexed keywords

ALDOSTERONE; CICLETANINE; CREATININE; PLACEBO; POTASSIUM; PROSTAGLANDIN; PROTEIN; SODIUM; TRICHLORMETHIAZIDE;

ALDOSTERONE BLOOD LEVEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIURETIC ACTIVITY; DRUG EFFECT; MALE; NATRIURESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PROSTAGLANDIN URINE LEVEL; PROTEIN URINE LEVEL; RAT; SALT LOADING; SODIUM BLOOD LEVEL; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; URINE VOLUME;

6-KETOPROSTAGLANDIN F1 ALPHA; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY WEIGHT; CREATININE; DINOPROSTONE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION, RENAL; KIDNEY FAILURE; MALE; NEPHRECTOMY; PYRIDINES; RATS; RATS, INBRED SHR;

EID: 0032986839     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.1999.03021.x     Document Type: Article

References (32)

1. 1. Bouthier JA, Safer ME, Deschamps E, Tarrade T. Haemodynamic effects of an antihypertensive diuretic substance on the forearm circulation of patients with essential hypertension. Drugs Exp. Clin. Res. 1988; 14: 221-4.
2. 2. Castro A, Parro L, Fuentes JA. Studies on the mechanism of action of the antihypertensive agent cicletanin. Arch. Mal. Coeur 1989; 82: 51-4.
3. 3. Malherbe E, Auget M, Delaflotte S et al. Antihypertensive profile of cicletanion, a furopyridine derivative: Comparison with captopril, indapamide and prazocine. Pharmacol. Res. Commun. 1988; 20 (Suppl. III): 121-33.
4. 4. Dorian B, Rarrue J, Defeudis FV, Sarari H, Borgeat P. Activation of prostacyclin synthesis in cultured aortic smooth muscle cells by diuretic-antihypertensive drugs. Biochem. Pharmacol. 1984; 33: 2265-9.
5. 5. Bukoski RD, Wagman DW, De Wan P, Xue H. Vascular actions of cicletanine. Arch. Mal. Coeur 1989; 82: 45-50.
6. + +-regulated protein kinase and relationship to vasorelaxation by cicletanine. J. Pharmacol. Exp. Ther. 1991; 257: 382-91.
7. 7. Uehara Y, Numabe A, Hirawa N et al. Antihypertensive effects of cicletanine and renal protection in Dahl salt sensitive rats. J. Hypertens. 1991; 9: 719-28.
8. 8. Auguet M, Guillon JM, Delaflotte S et al. In vivo and in vitro effects of cicletanin in spontaneously hypertensive rats. Drugs Exp. Clin. Res. 1988; 14: 89-95.
9. 9. Nakamoto H, Suzuki H, Katsumata H, Ohishi A, Saruta T, Sakaguchi H. Effects of carvedilol on renal function and blood pressure in three-fifth nephrectomised spontaneously hypertensive rats loaded with high salt. Drugs 1988; 36 (Suppl. 6): 160-4.
10. 10. Katsumata H, Suzuki H, Ohishi A, Nakamoto H, Saruta T, Sakaguchi H. Effects of antihypertensive agents on blood pressure and the progress of renal failure in partially nephrectomised spontaneously hypertensive rats. Lab. Invest. 1990; 62: 474-80.
11. 11. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin-phenol reagent. J. Biol. Chem. 1951; 193: 265-75.
12. 12. Haber E, Koerner T, Page LB, Kliman B, Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J. Clin. Endocrinol. Metab. 1969; 29: 1949-55.
13. 13. Ogihara T, Iinuma K, Nishi K et al. A non-chromatographic non-extraction radioimmunoassay for serum aldosterone. J. Clin. Endocrinol. Metab. 1977; 45: 726-31.
14. 14. Granstrom E, Lindgren FA. Radioimmunoassay of prostaglandins and related compounds. In: Curtis-Prior PB (ed.). Prostaglandins: Biology and Chemistry of Prostaglandins and Related Eicosanoids. Bath Press, London. 1989; 115-26.
15. 15. Nakamoto H, Suzuki H, Murakami M et al. Different effects of low and high doses of endothelin on hemodynamics and hormones in the normotensive conscious dogs. J. Hypertens. 1991 ; 9: 337-44.
16. 16. Raij L, Azar S, Keane WF. Mesangial immune injury, hypertension and progressive glomerular damage in Dahl rats. Kidney Int. 1984; 26: 137-43.
17. 17. Jin H, Yang RH, Chen YF, Durand J, Wyss JM, Oparil S. Antihypertensive effect of cicletanine is exaggerated in NaCl-sensitive hypertension. Am. J. Hypertens. 1990; 3: 104A (Abstract).
18. 18. Singer DR, Markandu ND, Sugden AL, MacGregor GA. A comparison of the acute effects of cicletanine and bendrofluazide on urinary electrolytes and plasma potassium in essential hypertension. Eur. J. Clin. Pharmacol. 1990; 39: 227-32.
19. 19. Dupont AG. The place of diuretics in the treatment of hypertension: A historical review of classical experience over 30 years. Cardiovasc. Drugs Ther. 1993; 7 (Suppl. 1): 55-62.
20. 20. Frolich JC. Prostacycline in hypertension. J. Hypertens. 1990; 8 (Suppl. 4): S73-8.
21. 21. Sato M, Abe K, Yasujima M et al. Inhibitory effect of cicletanin on vascular smooth muscle cell proliferation. Arch. Mal. Coeur 1989; 82: 63-6.
22. 22. Ishimitsu T, Uehara Y, Ishii M, Matsuoka M, Ikeda T, Sugimoto T. Roles of endogenous vasodepressor prostaglandins in growth of vascular smooth muscle cells in spontaneously hypertensive rats. Jpn. Circ. J. 1990; 54: 1546-53.
23. 23. Floege J, Topley N, Resch K. Regulation of mesangial cell proliferation. Am. J. Kidney Dis. 1991; 17: 673-6.
24. 24. Lin M, Ito H, Akimoto H et al. Cicletanine inhibits endothelin-1-induced hypertrophy of rat cardiomyocytes. Oyo Yakuri 1996; 51: 1-6.
25. 25. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cell. Nature 1988; 332: 411-15.
26. 26. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989; 78: 225-8.
27. 27. Takuwa N, Takuwa Y, Yanagisawa M, Yamashita K, Masaki T. A novel vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turnover in Swiss 3T3 fibroblasts. J. Biol. Chem. 1989; 264: 7856-61.
28. 28. Ito H, Hirata Y, Hiroe M et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ. Res. 1991; 69: 209-15.
29. 29. Sneddon JM, Vane JR. Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc. Natl Acad. Sci. USA 1988; 85: 2800-4.
30. 30. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived relaxing factor. Nature 1986; 320: 454-6.
31. 31. Uehara Y, Kawabata Y, Hirawa N et al. Possible radical scavenging properties of cicletanine and renal protection in Dahl salt sensitive rats. Am. J. Hypertens. 1993; 6: 463-72.
32. 32. Ohishi A, Suzuki H, Nakamoto H, Katsumata H, Saruta T. Differences in the effects of angiotensin converting enzyme inhibitors with or without a thiol group in chronic renal failure in rats. Clin. Sci. 1988; 76: 353-6.